DMAA

+ Watchlist + Portfolio

Drugs Made In America Acquisition Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.72
52-Week Range: $10.22 – $10.73
Market Cap: $260.37M
P/E (TTM): 59.58
EPS (TTM): 0.18
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.03
Debt/Equity: —
Total Debt: $100.00K
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: 18.80%
Enterprise Value: $361.20M

DMAA Income statement, annual periods, in USD
USD	FY2025
Revenue	$0.00
Selling, General & Admin	$2.82M
Operating Expenses	$2.82M
Operating Income	-$2.82M
EBITDA	-$2.82M
Pretax Income	$5.94M
Net Income	$5.94M
Diluted EPS	0.19
Diluted Shares	31.64M

DMAA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Selling, General & Admin	$330.93K	$131.92K	$263.70K	$2.09M	$143.30K
Operating Expenses	$330.93K	$131.92K	$263.70K	$2.09M	$143.30K
Operating Income	-$330.93K	-$131.92K	-$263.70K	-$2.09M	-$143.30K
EBITDA	-$330.93K	-$131.92K	-$263.70K	-$2.09M	-$143.30K
Pretax Income	$1.25M	$2.29M	$2.18M	$212.96K	$1.97M
Net Income	$1.25M	$2.29M	$2.18M	$212.96K	$1.97M
Diluted EPS	0.05	0.07	0.07	—	0.06
Diluted Shares	25.51M	33.52M	33.52M	—	33.72M

DMAA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$923.00	$822.00	$717.00	$6.14K	$14.89K
Current Assets	$71.02K	$49.73K	$28.20K	$12.19K	$14.89K
Total Assets	$232.81M	$235.21M	$237.63M	$239.92M	$242.04M
Current Liabilities	$347.37K	$301.44K	$456.61K	$376.17K	$492.17K
Total Debt	$60.90K	—	—	—	$100.00K
Total Liabilities	$7.25M	$7.20M	$7.36M	$7.28M	$7.39M
Retained Earnings	-$6.33M	-$6.46M	-$6.72M	-$7.27M	-$7.38M
Shareholders' Equity	$225.56M	$228.00M	$230.28M	$232.64M	$234.64M
Working Capital	-$276.35K	-$251.72K	-$428.42K	-$363.98K	-$477.28K
Net Debt	$59.98K	—	—	—	$85.11K

DMAA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$251.24K	-$106.66K	-$56.11K	-$125.18K	-$91.25K
Free Cash Flow	-$251.24K	-$106.66K	-$56.11K	-$125.18K	-$91.25K
Investing Cash Flow	-$231.15M	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$231.40M	$106.55K	$56.00K	$130.60K	$100.00K
Net Change in Cash	-$428.00	-$101.00	-$105.00	$5.42K	$8.75K

Market Snapshot

About

Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) formed to identify and merge with a target business in the pharmaceutical or healthcare manufacturing sector. The company's stated focus is on businesses involved in reshoring pharmaceutical production to the United States. Like all SPACs, Drugs Made In America has a limited timeframe to complete a business combination or return capital to shareholders. Until a merger is completed, the company holds investor proceeds in trust.

USD	FY2025
Operating Cash Flow	-$539.19K
Free Cash Flow	-$539.19K
Investing Cash Flow	-$231.15M
Financing Cash Flow	$231.69M
Net Change in Cash	$4.79K